Welcome to our dedicated page for Bio-Rad Laboratories news (Ticker: BIO.B), a resource for investors and traders seeking the latest updates and insights on Bio-Rad Laboratories stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bio-Rad Laboratories's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bio-Rad Laboratories's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Bio-Rad Laboratories, Inc. (NYSE: BIO.B) will release its first-quarter 2023 financial results on May 4, 2023, after market close. A conference call is scheduled for 2 PM Pacific Time to discuss these results, with participation details available. Bio-Rad is recognized as a leader in life science research and clinical diagnostics, with a revenue of $2.8 billion in 2022. The company serves a wide range of customers including universities, hospitals, and biotech firms globally. For more information, the company’s Investor Relations section offers access to the webcast of the call. This will provide insights into the company’s performance and strategic direction as it progresses through the fiscal year.
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) announced its participation in a fireside chat at Citi’s 2023 Healthcare Services, MedTech, Tools & HCIT Conference. The event is scheduled for Thursday, March 2, 2023, at 11:45 AM Eastern Time (8:45 AM Pacific Time). A live webcast and replay will be available on the Investor Relations section of Bio-Rad's website. With over 70 years of expertise, Bio-Rad leads in life science research and clinical diagnostics, serving various sectors including healthcare and biotechnology. The company had approximately $2.8 billion in revenues in 2022, employing around 8,300 staff worldwide.
Bio-Rad Laboratories (BIO, BIOb) reported Q4 2022 net sales of $730.3 million, down 0.3% from Q4 2021, primarily due to a significant drop in COVID-related revenue. Life Science sales rose 10.1%, while Clinical Diagnostics declined 8.7%. Net income surged to $827.7 million, or $27.78 per share, from a net loss of $1.57 billion in Q4 2021, driven by fair market value changes in equity securities. For FY 2022, total sales decreased 4.1% to $2.8 billion, with a net loss of $3.63 billion. The company projects 6-7% non-GAAP currency-neutral revenue growth in 2023, citing a strong market recovery and operational improvements.